We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Ava3.6

Avanafil (Stendra) Research

Mostly mechanism / observational

28 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Avanafil (Stendra) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2010–2023.

Based on 28 studies · 11 meta-analyses · 13 RCTs

Confidence

High confidence

By outcome

Erectile functionPhase-3 RCT and meta-analytic evidence for clinically meaningful improvement in erectile function versus placebo, including in men with diabetes; often effective within ~15-30 minutes · ~15-30 minutes (on-demand)
Mostly mechanism / observational22 studies
Cardiovascular & vascular
Too few graded studies1 study

Steady research

7 studies in the last 5 years · Latest meta-analysis: 2021

201020162023

1Meta-Analysis2019

Li J, Peng L, Cao D, He L, Li Y, Wei Q · Am J Mens Health (2019)

Avanafil (Stendra) Research

Mostly mechanism / observational

Avanafil for the Treatment of men With Erectile Dysfunction: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.

The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis.

The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis.

Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.

Avanafil for male erectile dysfunction: a systematic review and meta-analysis.

Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.

Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.

Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.

Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis.

Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.

The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review.

Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.

Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.

A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.

Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.

A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction.

Evaluation of daily avanafil efficacy in improving the endothelial function in Egyptian males with erectile dysfunction.

Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.

Efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction: A randomized, double blind, multicenter clinical trial.